{
  "docId": "019de071-eb84-776b-8e7d-ce40a476afec",
  "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02",
  "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 42,
  "pageCount": 105,
  "prevPage": 41,
  "nextPage": 43,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "SAD = Single Ascending Dose; MAD = Multiple Ascending Dose; LLOQ = Lower Limit of Quantitation; HS = Hidradenitis Suppurativa; AD = Atopic Dermatitis.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/42",
  "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec",
  "deckJsonHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec.json",
  "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-42",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.69
      },
      "kind": "list",
      "text": "Prolonged suppression of IRAK4 in blood and skin for at least 14-21 days with KT-474 multi-dosing shown to be safe and well-tolerated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b800bb0-7d9f-4a22-85e5-ea349088e22d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.77
      },
      "kind": "list",
      "text": "On track to initiate open-label cohort in HS and AD patients in Q1 next year with data read-out planned for mid-year, followed thereafter by start of Phase 2 studies in multiple indications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7129c3ef-6dc3-4aeb-9920-5aef3508049c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.91,
        "x": 0.06,
        "y": 0.53
      },
      "kind": "list",
      "text": "While cytokine results at 200 mg not currently available, even greater inhibition anticipated at that dose given the substantial increase in plasma exposure and tissue degradation (e.g. skin) and 94% IRAK4 reduction in monocytes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86d2e2d9-5770-494a-ab42-fbe37ad650bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.31
      },
      "kind": "list",
      "text": "Marked reduction of IRAK4 protein in blood and skin to near LLOQ of highly quantitative and sensitive mass spectrometry assay achieved at a dose of 100-200 mg daily x 14 days",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a31dbb1d-133b-41b3-a294-23b108ba5ad6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.94,
        "x": 0.03,
        "y": 0.41
      },
      "kind": "list",
      "text": "Strong and broad inhibition of whole blood ex vivo cytokine induction in MAD comparable to what was seen at highest SAD dose (1600 mg) demonstrated in association with >90% IRAK4 reduction in monocytes at 100 mg daily dose",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa24a6e6-61eb-4149-99a4-3fc7cf487f5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.94,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "list",
      "text": "Healthy volunteer SAD dose escalation completed; MAD enrolled through Cohort 4 (200 mg), with proof of mechanism (IRAK4 degradation) and proof of biology (broad inhibition of cytokine induction) established in SAD and at substantially lower doses in MAD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec575277-665f-47f6-b72e-8408977fa557",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.91,
        "x": 0.06,
        "y": 0.63
      },
      "kind": "list",
      "text": "High sensitivity CRP levels in plasma too noisy over time to detect meaningful changes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f55aa4b8-d8a3-438e-928e-06535be6b70c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.56,
        "x": 0.22,
        "y": 0.04
      },
      "kind": "title",
      "text": "Summary of Phase 1 KT-474 SAD/MAD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65b682d5-73cd-4546-bf8b-33f01f985a86",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}